News

Since its founding in 2013, the International Working Group on Neurotransmitter related Disorders (iNTD) has been building a network and patient registry aimed at promoting knowledge and awareness among clinicians on rare neurotransmitter disorders, including aromatic l-amino acid decarboxylase (AADC) deficiency. Over the past several years, the collaboration has expanded…

Gene therapy has demonstrated the ability to improve motor function in movement disorders, including ones triggered by aromatic L-amino acid decarboxylase (AADC) deficiency, a study reports. According to the researchers, better motor performance observed in children with AADC deficiency after undergoing gene therapy may be associated with improvements in brain…

Drugs used in Parkinson’s disease were seen to increase muscle tone and reduce eyelid droopiness and involuntary upward deviation of the eyes in a boy with aromatic L-amino acid decarboxylase (AADC) deficiency. The case report, “Feeding difficulty and developmental delay for 8 months and nystagmus for…

A technique that measures the levels of different metabolites — the products of cellular metabolism — of dopamine could serve as a non-invasive method to diagnose AADC deficiency, a study says. The study, “Clinical Metabolomics to Segregate Aromatic Amino Acid Decarboxylase Deficiency From Drug-Induced Metabolite Elevations,” was published…

A recent report reviewing the use of gene therapy for Taiwanese patients with aromatic l‐amino acid decarboxylase (AADC) deficiency suggests that such strategies may one day lead to a cure for this condition. The report, “A review of aromatic l‐amino acid decarboxylase (AADC) deficiency in Taiwan,” was…

Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bath dissertation, she analyzed Brexit’s long-term…

With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,” warned Avraham Steinberg,…

Gene therapy using a special type of virus vector to deliver the functional DDC gene is well-tolerated and might improve motor development in children with aromatic l-amino acid decarboxylase (AADC) deficiency in the future, a Phase 1/2 clinical trial shows. The findings of the study, “Efficacy and safety of AAV2…

Rare diseases affect about 30 million Americans — roughly the same number as those with type 2 diabetes. Yet only 5 percent of the estimated 7,000 rare diseases known to science have cures or treatments approved by the U.S. Food and Drug Administration (FDA). Raising awareness of those illnesses and highlighting…

A new study has begun to unravel how heterozygous mutations in aromatic l-amino acid decarboxylase (AADC) deficiency patients affect protein function at the molecular level, providing evidence for a complementary function when the mutations R347Q and R358H both are present. The study, “Heterozygosis in aromatic amino acid decarboxylase…